Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1056-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 31, Iss. 2, 2015-02 ,pp. : 204-211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 726-733

John Wiley & Sons Inc

Access to resources Recommend Favorite